Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE Q1 2026 earnings

Reported May 5, 2026 · After market close

EPS-$0.74Miss by $0.08
EPS estimate-$0.66

Next report

Aug 4, 2026 (In 6 days)
EPS estimate-$0.71

Financials

Q1 2026

Income statement

See full
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$8.69B+748%

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Current ratio9×+0.9×

Versus estimates

Revenue

Q4 2025$90.5MMiss by $52.4M

Diluted EPS

Q1 2026-$0.74Miss by $0.08
Q4 2025-$0.70Miss by $0.04Q3 2025-$0.15Beat by $0.53Q2 2025-$0.49Beat by $0.24Q1 2025-$0.74Beat by $0.02Q4 2024-$0.81Beat by $0.08

Ask the moment Spyre Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Spyre Therapeutics, Inc. report Q1 2026 earnings?
Spyre Therapeutics, Inc. (SYRE) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Spyre Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Spyre Therapeutics, Inc. reported eps of $-0.74 for Q1 2026.
Did Spyre Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.66 by $0.08.
How did Spyre Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 0.0% from $-0.74.
Where can I find Spyre Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001636282-26-000051) and the 10-Q periodic report (0001636282-26-000050) directly on SEC EDGAR. The filing index links above go to sec.gov.